HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.01470307v1 2/6/1249    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Müller, D. Articles by Kettritz, R. Search for Related Content PubMed PubMed Citation Articles by Müller, D. Articles by Kettritz, R.

Niacin Lowers Serum Phosphate and Increases HDL Cholesterol in Dialysis Patients

Franz Volhard Clinic, Department of Nephrology and Hypertension, Medical Faculty of the Charité, HELIOS-Klinikum-Berlin, Berlin, Germany

Correspondence: Dr. Ralph Kettritz, Wiltbergstrasse 50, 13125 Berlin, Germany. Phone: +49-30-9417-2202; Fax: +49-30-9417-2206; E-mail: kettritz{at}charite.de

Background and objectives: Adverse effects complicate the use of drugs that are prescribed for phosphate control in dialysis patients. Alternative treatment options are needed.

Design, setting, participants, & measurements: Nicotinic acid inhibits intestinal phosphate reabsorption and increases HDL cholesterol. This study tested the phosphate-lowering and HDL-increasing effect of Niaspan (prolonged-release nicotinic acid) in patients who were undergoing dialysis. Efficacy, safety, and tolerability of Niaspan were prospectively studied. Twenty dialysis patients, who were receiving a stable dosage of a calcium salt–containing drug for phosphate control, received after a 2-wk washout period Niaspan for 12 wk. Patients were started on 375 mg/d, and the dosage was increased every 2 wk to achieve 500, 1000, 1500, and 2000 mg/d, respectively. Clinical and laboratory parameters were prospectively recorded in patients who tolerated a target dosage of 1000 mg/d.

Results: Seventeen patients tolerated 1000 mg/d Niaspan (mean dosage 1470 ± 110 mg/d). Niaspan treatment for 12 wk decreased serum phosphate values from 7.2 ± 0.5 to 5.9 ± 0.6 mg/dl (P < 0.015). In contrast, Niaspan did not affect serum calcium levels. A significant increase in HDL cholesterol from 40 ± 3.2 to 59 ± 5.5 mg/dl (34%) was also observed with Niaspan (P = 0.0005).

Conclusions: Niaspan effectively lowered serum phosphate levels and significantly increased HDL cholesterol. Niaspan may provide an alternative or adjunctive treatment option in dialysis patients.

This article has been cited by other articles:

				S. C. Cheng, D. O. Young, Y. Huang, J. A. Delmez, and D. W. Coyne A Randomized, Double-Blind, Placebo-Controlled Trial of Niacinamide for Reduction of Phosphorus in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1131 - 1138. [Abstract] [Full Text] [PDF]